Digipath, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Digipath, Inc., now rebranded as Hypha Labs, Inc., is a biotechnology company specializing in the development and commercialization of advanced technologies for functional and psychedelic mushrooms, with a particular focus on psilocybin synthesis. The company develops proprietary bioreactor designs and AI-driven methods for optimizing mycelium processing to efficiently extract active compounds, targeting the functional mushroom market in the United States and beyond. Hypha Labs offers innovative products including the Hypha Micropearl accelerator, an in-home device designed to produce mushroom-based nutrient ingredients with greater potency and lower costs, expected to launch commercially by the end of 2025. Previously active as a cannabis analytical testing firm through its wholly-owned subsidiary Digipath Labs, the company divested these assets in early 2024, marking a strategic shift away from cannabis testing toward mushroom biotechnology. Hypha Labs holds a growing patent portfolio with filings for novel mushroom processing devices and methods and focuses on delivering scientific innovations to the psychedelic and functional mushroom industries, leveraging technology such as AI and machine learning. The company, founded in 2014 and headquartered in Las Vegas, Nevada, also completed key executive leadership changes in 2024 to align with its new strategic focus. This repositioning leverages its scientific expertise to pioneer scalable and cost-effective solutions in the rapidly expanding mushroom market, valued at billions of dollars with strong growth prospects. Hypha Labs continues to advance research, development, and commercialization efforts as part of its evolving business model in the biotechnology sector.
Financial Survey: Suncast Solar Energy (OTCMKTS:SUNC) versus Hypha Labs (OTCMKTS:DIGP)
Head to Head Analysis: Suncast Solar Energy (OTCMKTS:SUNC) & Hypha Labs (OTCMKTS:DIGP)
Comparing Suncast Solar Energy (OTCMKTS:SUNC) and Hypha Labs (OTCMKTS:DIGP)
Contrasting Suncast Solar Energy (OTCMKTS:SUNC) & Hypha Labs (OTCMKTS:DIGP)
Head-To-Head Comparison: Suncast Solar Energy (OTCMKTS:SUNC) and Hypha Labs (OTCMKTS:DIGP)
Head-To-Head Analysis: Hypha Labs (OTCMKTS:DIGP) vs. Suncast Solar Energy (OTCMKTS:SUNC)
Critical Contrast: Suncast Solar Energy (OTCMKTS:SUNC) vs. Hypha Labs (OTCMKTS:DIGP)
Reviewing Hypha Labs (OTCMKTS:DIGP) and Suncast Solar Energy (OTCMKTS:SUNC)
Suncast Solar Energy (OTCMKTS:SUNC) & Hypha Labs (OTCMKTS:DIGP) Head to Head Comparison
Digipath Name and Symbol Change Approved, Company Begins Trading as Hypha Labs, Inc. (FUNI)
Hypha Labs' Revolutionary Psilocybin Bioreactor Nominated for Best New Product of 2024 by Santa Monica Daily Press
CORRECTION: Hypha Laboratories Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium Production
CORRECTION: Hypha Laboratories Retains Integrity Media for Investor Relations and Corporate Communications
Hypha Laboratories Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium Production
Hypha Laboratories Retains Integrity Media for Investor Relations and Corporate Communications
Hypha Labs Names Craig Ellins Chief Science Officer
Digipath Enters Psilocybin Industry and Changes Name
Hypha Labs, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Digipath Announces Record Earnings of $292,533 for Recent Quarter Ended June 30